Review papers with raw data transparency

1 Objective of the reviewed paper

The paper synthesizes existing evidence that the Na,K-ATPase β2 subunit (AMOG/β2) acts as an adhesion molecule in the CNS, summarizes conflicting experimental findings about homophilic vs heterophilic binding modes, proposes two candidate neuronal partners (TSPAN31 and RTN4), models trans-dimers in silico, and outlines experimental strategies to identify the neuronal receptor complex.

Central review sentence from the article: AMOG/β2 review summary

2 Strengths

• Comprehensive synthesis: collates genetic (knockout and knock-in mice), biochemical, cellular, in silico structural models, and prior adhesion assays into a coherent framework and practical experimental roadmap (coIP MS, proximity labeling, CRISPR screening, in situ crosslinking, FRET/BiFC) Proposed identification strategies
• Balanced presentation: authors explicitly state inconsistencies (e.g., β2 homophilic aggregation in CHO/MDCK versus lack of astrocyte-astrocyte binding in vivo) instead of cherry-picking supportive data Heterologous versus in vivo discrepancy
• Translational relevance: links AMOG/β2 loss to glioblastoma invasiveness and proposes how adhesion loss could influence pathology and therapy directions AMOG/β2 in glioma

3 Weaknesses, unresolved gaps, and methodological caveats

1. Primary limitation: no new experimental data — conclusions rest on secondary synthesis and on in silico/heterologous-system observations; therefore mechanistic claims remain provisional Review limitations
2. Over-reliance on heterologous aggregation assays: CHO/MDCK and U87-MG aggregation results are informative but may reflect nonphysiological glycosylation, membrane composition, or overexpression artifacts; authors note tunicamycin sensitivity implying glycosylation-dependent adhesion but do not resolve native glycoforms or stoichiometry Glycosylation and aggregation
3. Candidate selection needs stronger evidence: TSPAN31 and RTN4 are plausible but database-based nomination and indirect rationale (microdomain scaffolding or membrane presentation) require biochemical validation; alternative candidate classes (immunoglobulin CAMs, protocadherins, lectin-like receptors) are not exhaustively excluded TSPAN31 and RTN4 candidates
4. Ambiguity separating pump vs adhesion functions: murine genetics (β2 knockout lethal; β2/β1 knock-in rescue) suggest some phenotypes arise from pump dysfunction rather than loss of adhesion — disentangling electrochemical from structural roles remains incomplete and the review calls for but does not present decisive experiments to separate them Knockout and knock-in evidence

4 Recommendations and critical experiments to resolve the receptor question

The review itself lists strategies; below I rank and expand them by feasibility and discriminatory power.

1. Proximity labeling in neuron–astrocyte co-cultures using AMOG/β2-BioID or APEX expressed at endogenous-like levels in astrocytes with neuronal proteome capture; follow with streptavidin enrichment and quantitative MS; include controls: catalytically dead tag, and neuronal-only labeling. This directly captures near neighbors in native membrane microdomains Proximity labeling recommendation
2. Functional adhesion screen: express AMOG/β2 in nonadhesive cells (CHO/HEK) and screen a neuronal membrane protein cDNA library; isolate adherent pairs and deconvolute cDNAs. This yields direct functional ligands, and avoids some biochemical fragility issues noted in coIP Adhesion functional screen
3. Genome-wide CRISPR loss-of-function screen in neurons for genes required for adhesion to AMOG/β2-expressing astrocytes; use barcoded pooled sgRNA libraries and FACS to isolate adhesion-deficient neurons; validated hits would be high-confidence candidates for the receptor complex CRISPR adhesion screen
4. In vivo validation in organoids or conditional knockout mice: validate top candidates by neuron-specific conditional knockout or acute knockdown and assess astrocyte–neuron adhesion, synapse alignment, and behavioral/neurodevelopmental phenotypes; rescue with receptor re-expression or mutated forms lacking interaction patches.

5 Specific critical comments on data and inference

• The review correctly highlights glycosylation as key to β2 interactions (tunicamycin sensitivity and predicted N-glycans) but does not quantify species-specific glycoforms; this is crucial because glycoform heterogeneity can explain CHO vs astrocyte differences — so mass-spec glycoproteomics on endogenous β2 is needed Glycosylation role
• On candidate choice: TSPAN31 (a tetraspanin) is functionally plausible as a microdomain organizer, but by itself is unlikely to be the single trans ligand; tetraspanins usually act in cis to cluster receptors. RTN4 (NogoA) is membrane-associated and implicated in neurite inhibition; however, biochemical topology and luminal ER localization of many reticulons complicate a simple trans-binding model — authors note this but experimental membrane localization in neurons where AMOG contacts astrocytes must be proven TSPAN31 RTN4 commentary

6 Practical next steps and an actionable pipeline (concise)

1. Obtain primary rodent neuron–astrocyte co-cultures and confirm endogenous AMOG/β2 localization at contact sites by high-resolution immuno-EM and glycoform-specific antibodies.
2. Run AMOG-BioID in astrocytes with neuronal co-culture, streptavidin MS identification, and CRISPR validation of top 20 hits; cross-validate by heterologous adhesion assay with isolated candidate cDNAs.
3. Perform site-directed mutagenesis on predicted β2 interface residues (guided by the reviewed in silico models) and test loss-of-binding in both co-culture adhesion and proximity labeling assays.

These steps follow recommendations already present in the review and prioritize discovery methods with high specificity for membrane complexes (proximity labeling + functional genetics) over fragile detergent-dependent coIPs coIP caveats

7 Overall evaluation scores

8 Key takeaways and confidence

• The review convincingly frames AMOG/β2 as a biologically important adhesion module in the CNS with unresolved receptor identity and plausible experimental approaches to find it AMOG importance statement
• Primary unknowns that could change the conclusion: identification of a bona fide neuronal receptor (or demonstration of physiologic homophilic β2 binding in vivo), characterization of endogenous glycoforms, and separation of pump vs adhesion phenotypes in vivo.
• Confidence in the review synthesis: moderate (roughly 7/10) because claims are conservative and well signposted, but the field requires the experimental steps the review prescribes.

9 Immediate lab actions suggested

If you are a lab planning to follow this work: implement AMOG-BioID in primary astrocytes co-cultured with neurons, followed by CRISPR adhesion screens and targeted glycoproteomics of endogenous β2. Prioritize orthogonal validation (FRET/BiFC and conditional knockout in organoids).